Hopace-MT 50 Tablet ER is a combination antihypertensive medication containing Metoprolol Succinate 50 mg and Ramipril 5 mg, designed for extended-release administration. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and decreasing myocardial oxygen demand. Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, promotes vasodilation by inhibiting the conversion of angiotensin I to angiotensin II, reducing peripheral vascular resistance and aldosterone secretion. This synergistic combination effectively manages hypertension and reduces the risk of cardiovascular events such as myocardial infarction and stroke. Hopace-MT 50 Tablet ER is indicated for patients requiring multi-mechanistic blood pressure control, particularly those with concomitant cardiac conditions like ischemic heart disease or heart failure. The extended-release formulation ensures a consistent plasma concentration, enhancing therapeutic efficacy and improving patient compliance by allowing once-daily dosing. Caution is advised in patients with bradycardia, hypotension, renal impairment, or a history of angioedema. Common adverse effects may include dizziness, fatigue, cough, and gastrointestinal disturbances. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Hopace-MT 50 Tablet ER should be used under medical supervision to optimize cardiovascular outcomes safely.